Showing 1 - 10 of 13
Persistent link: https://www.econbiz.de/10012237974
Persistent link: https://www.econbiz.de/10003827717
Persistent link: https://www.econbiz.de/10008698742
We develop a model of pandemic risk management and firm valuation. We introduce aggregate transmission shocks into an epidemic model and link valuations to infections via an asset-pricing framework with vaccines. Infections lower earnings growth but firms can mitigate damages. We estimate a...
Persistent link: https://www.econbiz.de/10012481801
We develop an integrated theory of investment, seasoned equity offerings (SEOs), liquidation, and corporate savings …
Persistent link: https://www.econbiz.de/10013044990
Entrepreneurs face significant non-diversifiable business risks. We build a dynamic incomplete markets model of entrepreneurial finance to demonstrate the important implications of nondiversifiable risks for entrepreneurs' interdependent consumption, portfolio allocation, financing, investment,...
Persistent link: https://www.econbiz.de/10012463800
The real options framework has been used extensively to analyze the timing of investment under uncertainty. While standard real options models assume that agents possess a constant rate of time preference, there is substantial evidence that agents are very impatient about choices in the...
Persistent link: https://www.econbiz.de/10012466627
Hedge fund managers are compensated via management fees on the assets under management (AUM) and incentive fees indexed …
Persistent link: https://www.econbiz.de/10012461815
We develop a model of pandemic risk management and firm valuation. We introduce aggregate transmission shocks into an epidemic model and link valuations to infections via an asset-pricing framework with vaccines. Infections lower earnings growth but firms can mitigate damages. We estimate a...
Persistent link: https://www.econbiz.de/10012833123
We develop a model of pandemic risk management and firm valuation. We introduce aggregate transmission shocks into an epidemic model and link valuations to infections by using an asset-pricing framework that accounts for vaccines. Infections lower earnings growth but firms can mitigate damages....
Persistent link: https://www.econbiz.de/10012834259